TY  - JOUR
T1  - INcomplete financial disclosures in an editorial, clinical crossroads, and reply letter related to herpes zoster
AU  - Whitley RJ
Y1  - 2010/02/24
N1  - 10.1001/jama.2010.109
JO  - JAMA
SP  - 733
EP  - 734
VL  - 303
IS  - 8
N2  - 
To the Editor:  I would like to report incomplete financial disclosures related to an Editorial,1 a Clinical Crossroads article,2 and a subsequent reply to a letter to the editor3 published in JAMA. This resulted from my misinterpretation of JAMA requirements for reporting conflicts of interest. As I noted previously,1- 3 I am on the board of directors of Gilead Sciences and a consultant for Chimerix; I receive compensation and stock from both companies. Neither company is involved in the development of drugs to treat herpesvirus infections. However, I did not report 3 financial disclosure issues.

SN  - 0098-7484
M3  - doi: 10.1001/jama.2010.109
UR  - http://dx.doi.org/10.1001/jama.2010.109
ER  -